Treats migraine with or without aura. ANDA 216998, held by Leading. Frovatriptan Succinate.
As of Nov 16, 2026, ANDA 216998 (Frovatriptan Succinate), held by Leading, was first approved by FDA on Apr 16, 2025, with 0 approved supplements and 0 published complete response letters.
Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks. Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Frovatriptan SuccinateEQ 2.5MG BASE · tablet;oral | Frovatriptan Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters